Navigation Links
Discovery Labs to Present AFECTAIR® Data at European Congress on Pediatric and Neonatal Ventilation
Date:6/7/2012

WARRINGTON, Pa., June 7, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced it will be presenting neonatal AFECTAIR® data at the 11th European Congress on Pediatric and Neonatal Ventilation being held June 6 – 9, 2012 in Montreux, Switzerland.  Though initially presented in the U.S., these data presentations mark the first introduction of the AFECTAIR neonatal device through scientific exchange to a European pediatric critical care audience.  The AFECTAIR neonatal device has been developed by Discovery Labs to simplify the delivery of inhaled medications for critical care patients requiring ventilatory support and was cleared for marketing in the U.S. in early 2012.  The AFECTAIR neonatal device will be commercially available in the U.S. and EU in late 2012.  

Highlights from the two data presentations include:

Utilization of iNO Using a Novel Ventilator Circuit Connector versus Standard of Care Under Simulated Neonatal Mechanical Ventilation Conditions – An In Vitro Study.  Mazela, et al.

  • The Standard of Care (SoC) for ventilator delivery of inhaled nitric oxide (iNO) in pulmonary hypertension allows for potential iNO dilution, gas loss and environmental contamination.
  • According to this study, which simulated neonatal mechanical ventilation conditions using an in vitro model, use of the AFECTAIR neonatal device resulted in the achievement of target nitric oxide concentrations using less nitric oxide when compared to the SoC delivery apparatus. 

In Vitro Assessment of a Novel Aerosol Delivery System under Simulated Conditions; Mazela, et al.

  • According to this study conducted in an in vitro model of neonatal mechanical ventilation conditions, when compared with a conventional wye connector, use of the AFECTAIR neonatal device resulted in improved delivery of aerosolized albuterol sulfate, including:     
    • a nine-fold increase in delivered dose under simulated CPAP conditions
    • a 14-fold increase in delivered dose under simulated mechanical ventilation conditions
    • a smaller difference in particle size distribution between aerosol output from the nebulizer and aerosol output from the patient interface.

These data will be presented on June 8th at the Montreux Congress Center.

About Discovery Labs

Discovery Laboratories, Inc. is a specialty biotechnology company with one focus – to create life-saving products for critical care patients with respiratory disease and improve the standard of care for pulmonary medicine. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, lyophilized and aerosolized formulations. Discovery Labs is also developing its proprietary drug delivery technologies – capillary aerosol generator and novel patient interface connectors – to enable efficient, targeted upper respiratory or alveolar delivery of aerosolized KL4 surfactant. Discovery Labs believes that its proprietary technology makes it possible, for the first time, to develop a significant pipeline of surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.discoverylabs.com.

Forward Looking Statements

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Examples of such risks and uncertainties, including those related to Discovery Labs' development activities, including preclinical activities exploring the potential utility of the AFECTAIR neonatal device, are described in Discovery Labs' filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Except as otherwise required by law, Discovery Labs undertakes no obligation to update or revise any forward-looking statements.


'/>"/>
SOURCE Discovery Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Discovery Labs Reports First Quarter 2012 Financial Results
2. Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing
3. AnaptysBio Announces Antibody Discovery Partnership With Gilead Sciences
4. UWM discovery advances graphene-based electronics
5. Mars, Incorporated Answers Question: How Does Feeding People and Pets Nurture Science and Discovery? At TEDMED 2012
6. AlphaBio Centrix, LLC Announces a New Discovery for Programming Energetic Patches
7. Discovery in Nature elucidates immune cells in skin and supports novel vaccine approach
8. Thomson Reuters Cortellis Drives Drug Discovery and Development With Powerful New Web Services
9. Discovery opens door to low-cost negative refraction, new products and industries
10. AnaptysBio Announces New Strategic Antibody Discovery
11. Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
Breaking Biology News(10 mins):